We are improving the lives of people suffering from mental illness and substance use disorders
What we do
HQ & Pipeline
Digital Therapeutics
Discover our story
Key News
SEPTEMBER 9, 2022
Orexo´s partner announces the result from the phase 2 study for OXMPI
SEPTEMBER 7, 2022
Trinity Health announces the availability of vorvida® and deprexis® to patients
SEPTEMBER 1, 2022
First patent issued for Orexo´s adrenaline product in Europe
Listed on Nasdaq Stockholm´s mainlist
Orexo is listed on Nasdaq Stockholm´s mainlist, Mid Cap, (ORX), and can be traded in the US at the OTCQX Market (ORXOY).
MODIA® - our digital therapy for opioid use disorder
- to be used along with pharmaceuticals
- 180 days treatment
- grounded in cognitive behavioral therapy techniques
- available 24/7
- ongoing clinical trial incl. up to 400 patients
News Flow
Press Releases & News
Orexo’s partner Gesynta Pharma has announced phase II study results from the OX-MPI (GS-248) project
Orexo’s partner Trinity Health today announces the availability of vorvida® and deprexis® to patients
First patent issued in Europe for Orexo’s adrenaline product OX640
Orexo to participate in Pareto Securities´ 13th Annual Healthcare Conference
Orexo Social
@OrexoABpubl
7 October 2022
At NLS Days, we co-hosted the US Pavilion. Along with our partners we showed good examples of how US-Nordic partner… https://t.co/1AA80NVDa1
@OrexoABpubl
5 October 2022
Very proud that our talented colleague Tanya Hughes, Director of Payer Channel Marketing, recently presented at an… https://t.co/UMVNx4QkzM
@OrexoABpubl
26 September 2022
Crossing the Atlantic building🆙a US commercial platform paved the way for a broader & stronger#Orexoo. Today we are…https://t.co/3N8ah6Hu099
Financial Snapshot
Group net revenues
597 MSEK
LTM1
Group EBITDA
-126 MSEK
LTM1
US Pharma segment EBIT
312 MSEK
LTM1
Cash position
468 MSEK
Q2 2022
1 Last Twelve Months, Q321-Q222, for more information about financial development Link